The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Overview of ICI colitis and its effect on cancer treatment
Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses immune checkpoint inhibitor (ICI) colitis, a significant immune-related adverse event (irAE) in cancer immunotherapy. ICIs have greatly improved cancer treatment but can cause colitis, leading to severe inflammation, treatment interruptions, and worse outcomes if not managed. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MIMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – BioNTech; Ilya Pharma; IOTA Pharmaceuticals; Janssen; Kanvas Biosciences; Mallinckrodt; Sorriso Pharmaceuticals
Patents, Royalties, Other Intellectual Property – Springer
